SCHEMBL23218388

SCHEMBL23218388

COc1ccc(CC(=O)O)c(OCc2coc3ccc(-c4cccc(CN)c4F)cc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.43
FFAR1 O14842 1/20 0.39
PPARD Q03181 2/20 0.39
CFD P00746 3/20 0.39
MTNR1A P48039 3/20 0.38
NQO2 P16083 1/20 0.38
MTNR1B P49286 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
F11 P03951 1/20 0.38
KLKB1 P03952 1/20 0.38
F7 P08709 1/20 0.38
TPSB2 P20231 1/20 0.38
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
PTGER1 P34995 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591230 1.00 CD274 (0.43) CD274FFAR1PPARDCFDMTNR1A
SCHEMBL23219111 0.90 TSHR (0.39) CD274MTNR1ANQO2MTNR1BMAPT
SCHEMBL29852466 0.90 TSHR (0.39) CD274MTNR1ANQO2MTNR1BMAPT
SCHEMBL29592710 0.89 CFD (0.49) CD274PPARDCFDPLGPLAU
SCHEMBL23218539 0.89 CFD (0.49) CD274PPARDCFDPLGPLAU
SCHEMBL23218484 0.89 CFD (0.40) CD274FFAR1CFDMTNR1ANQO2
SCHEMBL29591505 0.89 CFD (0.40) CD274FFAR1CFDMTNR1ANQO2
SCHEMBL23218126 0.88 CFD (0.42) CD274FFAR1PPARDCFDPLG
SCHEMBL29592059 0.88 CFD (0.42) CD274FFAR1PPARDCFDPLG
SCHEMBL23218831 0.85 CFD (0.52) FFAR1CFDMTNR1AMTNR1BPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CD274 2774/4885FFAR1 3516/4885PPARD 2085/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CD274 4001/4885FFAR1 3234/4885PPARD 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.